Key Takeaways
- Margin squeeze, cautious guide: FY22 EBITDA margin contracted to 17.4% from 24.7% on input and freight costs; management guided FY23 to a tight 17–20% range, signaling no quick relief.
- Revenue growth held up: FY22 revenue grew 8.3% YoY to ₹1,490 crores, with North America and Australia leading, even as US generics absorbed high single-digit price erosion.
- Balance sheet stretched operationally: Receivables rose to ~90 days as credit was extended to select customers, and inventory built up because India-to-US shipping times nearly tripled to 60 days.
- Building for a bigger future: A ₹200 crores CAPEX plan, Goa line expansion, API R&D for 6–7 products, and a Dubai acquisition all point to a medium-term bet on ₹2,000 crores revenue, but near-term returns are unproven.
- What to watch next quarter: Whether gross margin stabilizes in the promised 50–52% band, any sign that input costs actually stop rising, and the pace of US new product launches against ongoing price erosion.
Margin & Cost Structure
- Gross margin fell sharply in Q4: Q4 gross margin dropped to 49.4% from ~53% in Q3, driven by sustained higher input costs, elevated freight, and packaging material inflation tied to oil prices.
- Input cost drivers are external and sticky: China lockdowns hit raw material and chemical supply, while the Ukraine war and Russia embargoes pushed up oil and freight; management sees prices stabilizing at high levels but no reduction in the next six months.
- Freight timelines structurally longer: Shipments from India to the US now take about 60 days versus 21 days earlier, forcing the company to hold more inventory in leased US and UK warehouses to avoid stock-outs.
- Depreciation jumped on lease accounting: Q4 depreciation rose by ₹12 crores because of Ind AS 116 adoption for US and UK warehouses, with a ₹3 crore quarterly run-rate going forward.
- Tax rate lifted by one-time provision: The effective tax rate rose due to a ~₹7.8 crores deferred tax provision on capital leases; FY23 rate is expected at 22–24%.
- FY23 margin guide is cautious: Management expects EBITDA margin pressure to continue and guided to a 17–20% range for FY23, only marginally above the 17.4% delivered in FY22.
Jitendra Sharma: "We believe that this year the EBITDA margin pressure will continue and we are expecting the EBITDA in the range of 17% to 20%, the FY22 overall EBITDA was 17.4% and we expect the EBITDA to remain between 17% and 20% in this year."
US Generics & Pricing
- High single-digit price erosion persisted: US generic pricing pressure ran at high single digits through FY22, and management expects bottom-line pressure from input costs to continue even as sales grow year-on-year.
- New launches are the offset: The company launched 3 new products in the US in Q4 and expects 3 to 4 more in FY23, though management did not initially quantify the launch pipeline when asked about offsetting price erosion.
- Generic strategy targets early-entry molecules: The company does not develop its own NDAs but identifies generic molecules where it can achieve early launch and early timescales, with one such product hoped for in 2024.
- Market share defended: Despite pricing and cost headwinds, the company maintained market share and grew sales volumes in the US.
Mark Saldanha: "The bottomline pressure is always going to be very strong input cost, but definitely the sales pressure, I mean in the sales point of view, we too see a growth happening year-on-year..."
International Markets & Dubai Acquisition
- UK and Australia delivered strong growth: Australia grew 22.9% in FY22; the UK saw 12 product launches in Q4 alone, with 16 products already filed and awaiting approval and 8 more planned for FY23 filing.
- Dubai acquisition opens Middle East distribution: The company acquired a virtual formulation marketing company in Dubai as a platform for distribution into the Middle East, viewing Dubai as a port of entry into the region.
- Revenue doubling targeted: Management expressed confidence it can double the acquired company's revenue within two years once it takes over charge.
Mark Saldanha: "Dubai basically for us is a platform for distribution in the Middle East."
Capacity, API Strategy & CAPEX
- Goa expansion on track: A new manufacturing line is expected to start by the end of calendar year 2022, adding formulation capacity.
- ₹200 crores CAPEX underway: The plan covers both formulation and API capabilities; ₹46.3 crores was already incurred in FY22, with acquisitions also being explored for formulation manufacturing capacity.
- Organic API development progressing: R&D is underway on 6–7 products, and the company is hopeful of filing a few DMFs with its own API by the end of 2022.
- Inorganic API strategy stalled on valuations: Management found API company valuations "crazy" in 2020 and, though still exploring, has nothing concrete; the difficulty in identifying and valuing targets pushed the company toward the organic route.
- Madhya Pradesh Greenfield project: The company has applied for land allocation in Madhya Pradesh for a new Greenfield project, though no timeline was given.
Mark Saldanha: "2020, obviously API companies had crazy evaluations, so consummating or finding out the right partner was a bit difficult. Now that reality has seeped into 2021 and 22, we are still exploring that, nothing concrete has come onto that..."
Balance Sheet & Working Capital
- Receivables stretched to ~90 days: Trade receivables increased in line with sales growth, and credit periods were extended to certain customers in the US and UK due to market conditions; management does not expect it to go further and thinks it will remain around 90 days in coming quarters.
- Inventory build is deliberate: Extended logistics timelines (60-day shipping vs. 21 days earlier) prompted the company to hold more stock in leased US and UK warehouses to avoid stock-out positions.
- Finance costs rose on bank charges: The increase was driven by processing fees, LC opening charges, commitment charges on unutilized working capital limits, and the dividend on preference shares of Rs. 5 crores classified under finance charges.
- No immediate debt plans: Given cash generation and cash on books, management has no short-term plans to raise debt; longer term, any debt would stay within 1x EBITDA.
- Warrant conversion expected this year: 25% of the ₹93 crore warrant issue was received upfront; the balance is expected during the current year, though the company does not currently need the funds and will call for subscription closer to the 18-month due date unless an acquisition requires earlier conversion.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue target | ₹2,000 crores | Within 3 years |
| EBITDA margin | 17% to 20% | FY23 |
| Gross margin | 50% to 52% | FY23 |
| Effective tax rate | 22% to 24% | FY23 |
| R&D spend | Increase to 4%–5% of sales (from ~2% in FY22) | Over next few years |
| Goa manufacturing line | Start production | End of calendar year 2022 |
| API DMF filings | File a few DMFs with own API | By end of 2022 |
| US product launches | 3 to 4 new launches | FY23 |
| UK product filings | 8 products to file | FY23 |
| Dubai acquisition revenue | Double acquired company's revenue | Within 2 years of taking charge |
| Receivables | Remain around 90 days, no further increase expected | Coming quarters |
| Warrant conversion | Balance 75% money called | Sometime in current year, or earlier if acquisition requires |
| Debt | No short-term debt; longer-term debt not beyond 1x EBITDA | Ongoing |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| Operating revenue | ₹418 cr, +26.6% YoY vs ₹330 cr |
| Gross profit | ₹206 cr, +1.5% YoY |
| Gross margin | 49.4% |
| EBITDA | ₹63.6 cr |
| Profit before tax | ₹52.6 cr |
| Profit after tax | ₹29.7 cr |
| Total depreciation charge | ₹21 cr, includes ₹12 cr one-time catch-up for Ind AS 116 lease accounting on US and UK warehouses |
| Finance cost | ₹5 cr, vs ₹1 cr in Q3 FY22 and ₹3 cr in Q4 FY21 |
| FY22 revenue | ₹1,490 cr, +8.3% YoY |
| FY22 US / North America revenue | ₹635 cr, +8.5% YoY |
| FY22 EU & UK formulation revenue | ₹609 cr, +4.7% YoY |
| FY22 Australia / New Zealand formulation revenue | ₹179.8 cr, +22.9% YoY |
| FY22 EBITDA margin | 17.4%, vs 24.7% in FY21 |
| FY22 PAT | ₹186.8 cr |
| FY22 EPS | ₹4.51 |
| FY22 CAPEX | ₹46.3 cr |
| FY22 R&D spend | ₹30.2 cr, ~2% of sales; expected to increase to 4-5% of sales over next few years |
| Cash and cash equivalents | ₹349.3 cr |
| US price erosion (FY22) | Single high-digit percentage |
| Product launches in Q4 | 3 new products in US, 12 in UK |
| Product pipeline | >76 products total: 34 UK, 32 US (27 OTC, 5 RX), 10 Australia & New Zealand |
| UK pipeline detail | 8 products planned to file in FY23, 16 already filed and awaiting approval |
| Expected US launches in FY23 | 3 to 4 new launches |
| Average receivable days (FY22) | ~90 days |
| FY23 EBITDA margin guidance | 17% to 20% |
| FY23 gross margin guidance | 50% to 52% |
| FY23 effective tax rate guidance | 22% to 24% |
| Revenue target | ₹2,000 cr, expected within 3 years |
| Dubai acquisition cost | 1.3 cr AED, approximately ₹27-28 cr; existing revenue ~1.4 cr dirhams |
| Warrant issue | ₹93 cr, 25% received upfront, convertible within 18 months from 20 July 2021 |